CALCIUM SALTS OF INDOLE DERIVED STATINS

(19)

(11)

EP 1 515 717 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	16.12.2009 Bulletin 2009/51

(45)	Mention of the grant of the patent:
	01.10.2008 Bulletin 2008/40

(21)	Application number: 03740234.4

(22)	Date of filing: 12.06.2003

(51)

International Patent Classification (IPC):

A61K 31/405^(2006.01)

C07D 209/24^(2006.01)

(86)	International application number:
	PCT/EP2003/006195

(87)	International publication number:
	WO 2003/105837 (24.12.2003 Gazette 2003/52)

(54)	CALCIUM SALTS OF INDOLE DERIVED STATINS CALCIUMSALZE VON STATINEN AUS INDOL SELS DE CALCIUM DE STATINES DERIVEES D'INDOLE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30)

Priority:

13.06.2002 US 388318 P

(43)	Date of publication of application:
	23.03.2005 Bulletin 2005/12

(73)	Proprietors:
	Novartis AG 4056 Basel (CH) Designated Contracting States: BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR Novartis Pharma GmbH 1230 Wien (AT) Designated Contracting States: AT

(72)	Inventors:
	CHEN, Guang-Pei Livingston, NJ 07039 (US) KAPA, Prasad, Koteswara Parsippany, NJ 07054 (US) SUTTON, Paul, Allen Parsippany, NJ 07054 (US)

(74)	Representative: Morris, Clive Sydney
	Corporate Intellectual Property Novartis AG 4002 Basel 4002 Basel (CH)

(56)

References cited: :

EP-A- 0 547 000
US-A- 5 354 772

WO-A-02/36563

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).